2021 Research On Virginiamycin Market: Effect of dietary antibiotics on intestinal global metabolite levels by 2027

Global Virginiamycin Market Analysis

Overview

Virginiamycin is a streptogramin antibiotic developed by Streptomyces virginiae. It has two synergistic factors: M (hybrid polyketide-peptide) and S (synthetic polyketide-peptide) (peptide). It is used to eliminate microbial pollution in the fuel ethanol sector. Virginiamycin is an antibiotic that was first marketed in the U.S. in 1999 for ciprofloxacin enterococcus. It is also used in agriculture, especially in the animal industry, to help animals develop faster and avoid and cure infections. Virginiamycin is a compound made up of the two main components, virginiamycin M1 and virginiamycin S1. Virginiamycin inhibits bacterial protein synthesis, which inhibits microbial development in the gastrointestinal tract lumen.

Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2621

Virginiamycin can be used as a metabolic enhancer since it improves food intake and metabolism. It also increases the condition of the small intestine epithelium and prevents gut microbes from producing toxic toxins and metabolites. Virginiamycin is used to diagnose necrotic enteritis in broiler chickens, a lethal gastrointestinal disease that affects many birds.

Drivers

Pharmaceutical companies are focusing on introducing new drugs to counter Virginiamycin's reduced distribution and expand their market share. As a result, demand growth is projected to be boosted. Phibro Animal Health Corp. reported in January 2019 that the Veterinary Drugs Directorate (VDD) of Health Canada had approved its virginiamycin medicated grain additives for use in beef cattle. V-max (virginiamycin) is licensed by Phibro Animal Health Corp. for reducing the occurrence of liver abscesses in cattle fed in confinement.

Demand for livestock is rapidly increasing in developed countries. The market for livestock in developing countries is leveling off. The global virginiamycin market is expected to rise due to rising demand for livestock as the human population grows. Animal feed is in high demand as livestock production rises.

Tailored Information as per niche requirement:

LIMITED TIME OFFER - Hurry Up!

Exclusive offer!!! Purchase the report at a discounted rate!!!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2621

The global virginiamycin market is expected to be hampered by regulatory agencies' strict regulations. The European Commission adopted a regulation setting maximum residue levels for virginiamycin in poultry species in September 2015, which is applicable in the European Union.

About 105 metric tons of antibiotics were used as growth promoters in Denmark, but after a few years, their use ceased, which was followed by a decrease in tolerance to virginiamycin. In Denmark, Virginiamycin was outlawed in 1999. The early ban on growth promoters in Denmark resulted in a significant increase in surgical antibiotic use in the treatment of diseases like colibacillosis and ileitis. Additionally, symptoms of an allergic reaction to virginiamycin, such as maculopapular explosion, anaphylaxis reactions, atopic dermatitis appearance on initial areas of contact dermatitis, and lesions, are expected to limit the global virginiamycin market's expansion.

Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/2621

Regional Insights

The rapid growth in livestock animals is the primary reason for North America's dominance in the global virginiamycin market in terms of sales share over the projected period, led by Europe. The demand for virginiamycin has been increasing in this region due to the need for additional supplements in the diet for companion animals as well as farm animals for proper nutrition. In Europe, virginiamycin usage is high, which is expected to drive the region's virginiamycin market growth. Virginiamycin was approved for use in feed in January 2017. Both feed uses of virginiamycin alone or in combination would require the veterinary feed directive (VFD) until the voluntary conversion from over-the-counter to VFD is completed.

Competitive Landscape

The market's main players are concentrating on the production, manufacturing, and marketing of multisource and packaged pharmaceuticals, which is boosting market growth. In January 2017, Huvepharma AD received approval for the combination drug STAFAC (virginiamycin) plus CLINACOX (diclazuril) in chickens for the prevention of necrotic enteritis and coccidiosis in broiler chickens.

Major companies contributing in the global virginiamycin market are Manus Aktteva Biopharma, Phibro Animal Health Corporation, Xiamen ShengLang SaiChuang Biological Technology Co., Ltd., Elanco, Hongcong Xinrunde Chemical Co., Ltd, Vetoquinol, Ceva, Virbac, Zoetis, Merck Animal Health, and Alfanzyme.

Table of Content

Global Virginiamycin Market Research Report

Section 1: Global Virginiamycin Industry Overview

Section 2:  Global Economic Impact on Virginiamycin Industry

Section 3:  Global Market Competition by Industry Producers

Section 4:  Global Productions, Revenue (Value), according to Regions

Section 5:  Global Supplies (Production), Consumption, Export, Import, geographically

Section 6:  Global Productions, Revenue (Value), Price Trend, Product Type

Section 7:  Global Market Analysis, on the basis of Application

Section 8:  Virginiamycin Market Pricing Analysis

Section 9:  Market Chain, Sourcing Strategy and Downstream Buyers

Section 10:  Strategies and key policies by Distributors/Suppliers/Traders

Section 11:  Key Marketing Strategy Analysis, by Market Vendors

Section 12:  Market Effect Factors Analysis

Section 13:  Global Virginiamycin Market Forecast

Other Related News:

India Mucormycosis Treatment (Black Fungus Drugs) Market To Surpass US$ 11.7 Million By 2028

Canada Clinical Nutrition Market To Surpass US$ 828.5 Million By 2028

Urea Cycle Disorders Treatment Market To Surpass US$ 1,510.2 Million By 2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837